Skip to main content
Year archive

MorphoSys AG — 2022 filings

All 98 regulatory filings released by MorphoSys AG (MOR) in 2022, sourced directly from the official regulator.

98 Filings
2022 Period
2022 filings (98)
Filing Released Lang
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-29 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-29 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-29 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-29 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-29 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-23 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-23 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-23 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-12-23 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-23 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-22 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-12-22 English
Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
Board/Management Information
2022-12-20 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-15 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-14 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-13 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-12-13 English
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Regulatory Filings
2022-12-11 English
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
Regulatory Filings
2022-12-10 English
MorphoSys Out Licenses Pre-Clinical Oncology Program
Regulatory Filings
2022-12-06 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-06 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-12-05 English
Report Publication Announcement 2022
Report Publication Announcement
2022-12-02 English
Report Publication Announcement 2022
Report Publication Announcement
2022-12-02 English
MorphoSys AG: Financial Calendar 2023
Report Publication Announcement
2022-11-28 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-28 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-28 English
MorphoSys AG: Krisja Vermeylen, buy
Director's Dealing
2022-11-28 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-22 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-22 English
MorphoSys AG: Dr. Marc Cluzel, buy
Director's Dealing
2022-11-21 English
Q3 statement / Q3 financial report 2022
Interim / Quarterly Report 9M 2022
2022-11-17 English
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
Earnings Release 9M 2022
2022-11-16 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-16 English
MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimers Disease
Legal Proceedings Report
2022-11-14 English
Ad hoc: MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimers Disease
Legal Proceedings Report
2022-11-14 English
Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
Earnings Release 9M 2022
2022-11-10 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-10 English
MorphoSys to Share New Data on Pelabresib and Monjuvi (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Regulatory Filings
2022-11-03 English
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
Regulatory Filings
2022-10-27 English
GSK, MorphoSys Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
Regulatory Filings
2022-10-27 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-21 English
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Earnings Release Q3 2022
2022-10-21 English
Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Earnings Release Q3 2022
2022-10-21 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-12 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-11 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-10-10 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-06 English
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi (tafasitamab-cxix) for Patients with R/R DLBCL
Regulatory Filings
2022-09-28 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-09-22 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-09-19 English
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
Board/Management Information
2022-08-31 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-08-04 English
Half-yearly financial report 2022
Interim / Quarterly Report H2 2022
2022-08-04 German
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
Earnings Release Q2 2022
2022-08-03 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-08-01 English
MorphoSys AG: Invitation to MorphoSys Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
Report Publication Announcement
2022-07-28 English
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Earnings Release Q2 2022
2022-07-26 English
Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Earnings Release Q2 2022
2022-07-26 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-13 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-11 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-05 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-01 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-01 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-29 English
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
M&A Activity
2022-06-14 English
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Legal Proceedings Report
2022-06-13 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-06-10 English
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
Regulatory Filings
2022-06-10 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-08 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-03 English
MorphoSys AG Reports Outcome of Annual General Meeting 2022
AGM Information
2022-05-18 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-13 English
MorphoSys to Present New Data on Pelabresib and Monjuvi (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
Regulatory Filings
2022-05-12 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-11 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-09 English
Q1 statement / Q1 financial report 2022
Interim / Quarterly Report Q1 2022
2022-05-06 English
MorphoSys AG Reports First Quarter 2022 Financial Results
Earnings Release Q1 2022
2022-05-04 English
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
Report Publication Announcement
2022-04-28 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2022-04-20 English
Annual financial report 2021
Annual Report FY 2021
2022-04-20 English
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2022-04-06 German
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
Regulatory Filings
2022-03-22 English
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Earnings Release Q4 2021
2022-03-16 English
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Regulatory Filings
2022-03-15 English
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
Call Transcript
2022-03-10 English
Ad hoc: MorphoSys AG reports non-cash impairment charge of 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
Regulatory Filings
2022-03-10 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-23 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-21 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-18 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-03 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-02 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-01-31 English
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
Environmental & Social Information
2022-01-24 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2022-01-11 English
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
Investor Presentation
2022-01-10 English
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
Earnings Release FY 2021
2022-01-07 English
MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
Earnings Release FY 2021
2022-01-07 English